drugset / Trial / NCT01084174

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy

NCT01084174

Phase 1/2 Completed 21 enrolled Johns Hopkins University
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to explore the safety and efficacy of a sublingual (under the tongue) immunotherapy (SLIT) dosing regimen and an oral immunotherapy (OIT) regimen in inducing desensitization and long term tolerance in children with persistent peanut allergy.

Timeline

Start
2010-03
Primary completion
2012-01
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Peanut extract Unknown 3.7 mg Other
Subject Peanut powder Unknown 2000 mg Oral

Indications